Literature DB >> 22565233

Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms.

O Pogarell1, W Koch, S Karch, S Dehning, N Müller, K Tatsch, G Poepperl, H-J Möller.   

Abstract

Schizophrenia is a complex dynamic disorder comprising a wide range of neurobiological alterations including dopaminergic dysfunction. The aim of the study was to investigate dynamic changes of dopaminergic neurotransmission in patients with schizophrenia (n=8, mean age 25.4 ± 5.8 years) in early stages of the disorder, compared to healthy control subjects (n=7, mean age 23.6 ± 2.7 years). A dynamic IBZM SPECT protocol was used to assess the endogenous dopamine release following an amphetamine challenge. Subjects received a bolus activity of 175 MBq followed by a continuous infusion of 45 MBq/h [123I]IBZM. SPECT scans were performed 2 h after bolus injection, and 1 h following the amphetamine challenge (0.3 mg/kg). Striatal IBZM binding to dopamine D2 receptors was assessed with a volume-of-interest (VOI) technique. The change in IBZM binding between pre- and post-challenge scans was used as a measure of endogenous dopamine release triggered by amphetamine. At baseline, patients showed higher mean striatal IBZM binding compared to controls (0.77 ± 0.09 vs. 0.68 ± 0.07, p=0.07). There was a statistically significant difference in IBZM binding between patients, with a predominance of negative vs. positive symptoms (0.84 ± 0.08 vs. 0.71 ± 0.04, p<0.05). Upon amphetamine challenge, mean IBZM binding decreased by about 4.9 ± 7.6% in controls (n=7) compared to a mean of 12.4 ± 5.8% in subjects with schizophrenia (p<0.05). In patients, paranoid symptoms showed a significant negative correlation with IBZM baseline binding, whereas there was a trend towards positive correlation with the decrease of IBZM binding under challenge. Negative symptoms showed positive associations with baseline IBZM binding. The data are in line with previous reports and contribute to the notion of a dynamic instability of the dopaminergic system in patients with schizophrenia, taking into account the psychopathology with respect to positive or negative symptoms. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565233     DOI: 10.1055/s-0032-1306313

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  17 in total

Review 1.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

3.  A heuristic model for working memory deficit in schizophrenia.

Authors:  Zhen Qi; Gina P Yu; Felix Tretter; Oliver Pogarell; Anthony A Grace; Eberhard O Voit
Journal:  Biochim Biophys Acta       Date:  2016-05-10

Review 4.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

5.  Glutamatergic dysfunction is associated with phenotypes of VGF-overexpressing mice.

Authors:  Takahiro Mizoguchi; Honoka Fujimori; Takuya Ohba; Masamitsu Shimazawa; Shinsuke Nakamura; Masakazu Shinohara; Hideaki Hara
Journal:  Exp Brain Res       Date:  2022-05-19       Impact factor: 2.064

Review 6.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

Review 7.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.

Authors:  Oliver D Howes; Robert McCutcheon; Michael J Owen; Robin M Murray
Journal:  Biol Psychiatry       Date:  2016-08-06       Impact factor: 13.382

8.  Dopamine Transporter Is a Master Regulator of Dopaminergic Neural Network Connectivity.

Authors:  Douglas R Miller; Dylan T Guenther; Andrew P Maurer; Carissa A Hansen; Andrew Zalesky; Habibeh Khoshbouei
Journal:  J Neurosci       Date:  2021-05-12       Impact factor: 6.167

Review 9.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

Review 10.  Role of SHH in Patterning Human Pluripotent Cells towards Ventral Forebrain Fates.

Authors:  Melanie V Brady; Flora M Vaccarino
Journal:  Cells       Date:  2021-04-16       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.